Skip to Content
Merck
  • A p53-dependent translational program directs tissue-selective phenotypes in a model of ribosomopathies.

A p53-dependent translational program directs tissue-selective phenotypes in a model of ribosomopathies.

Developmental cell (2021-07-10)
Gerald C Tiu, Craig H Kerr, Craig M Forester, Pallavi S Krishnarao, Hannah D Rosenblatt, Nitin Raj, Travis C Lantz, Olena Zhulyn, Margot E Bowen, Leila Shokat, Laura D Attardi, Davide Ruggero, Maria Barna
ABSTRACT

In ribosomopathies, perturbed expression of ribosome components leads to tissue-specific phenotypes. What accounts for such tissue-selective manifestations as a result of mutations in the ribosome, a ubiquitous cellular machine, has remained a mystery. Combining mouse genetics and in vivo ribosome profiling, we observe limb-patterning phenotypes in ribosomal protein (RP) haploinsufficient embryos, and we uncover selective translational changes of transcripts that controlling limb development. Surprisingly, both loss of p53, which is activated by RP haploinsufficiency, and augmented protein synthesis rescue these phenotypes. These findings are explained by the finding that p53 functions as a master regulator of protein synthesis, at least in part, through transcriptional activation of 4E-BP1. 4E-BP1, a key translational regulator, in turn, facilitates selective changes in the translatome downstream of p53, and this thereby explains how RP haploinsufficiency may elicit specificity to gene expression. These results provide an integrative model to help understand how in vivo tissue-specific phenotypes emerge in ribosomopathies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
eIF4E/eIF4G Interaction Inhibitor, 4EGI-1, The eIF4E/eIF4G Interaction Inhibitor, 4EGI-1, also referenced under CAS 315706-13-9, controls the biological activity of eIF4E/eIF4G interaction. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Roche
Anti-Digoxigenin-AP, Fab fragments, from sheep
Sigma-Aldrich
Cycloheximide, from microbial, ≥94% (TLC)